Expert Interview
Discussing the standard of care of bladder cancer and the potential of Johnson & Johnson's TAR-200 "The preztel" and cetrelimab, a PD-1 inhibitor.
Ticker(s): JNJInstitution: Houston Metro Urology
- board certified urologist, Founder and President of Houston Metro Urology and has been in private practice serving patients throughout the Houston metropolitan area since 1984.
- Areas of interest include Urologic Oncology (prostate, bladder, and kidney cancers), benign disorders of the prostate, Erectile Dysfunction, and Robotic Assisted Surgery
- treats 100 patients with hypogonadism
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
